A Comparison of Immediate and Delayed Vitrectomy for the Management of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy
BACKGROUND AND OBJECTIVE:
To compare immediate and delayed vitrectomy for the management of vitreous hemorrhage (VH) due to proliferative diabetic retinopathy (PDR).
PATIENTS AND METHODS:
Retrospective review of 134 eyes receiving vitrectomy for non-clearing, PDR-associated VH. Primary outcome was area under the vision curve (AUC) in patients receiving immediate (< 30 days) versus delayed (> 30 days) vitrectomy with endolaser.
Forty-six eyes were included, with 17 undergoing immediate (< 30 days) vitrectomy with endolaser and 29 undergoing delayed (> 30 days) vitrectomy with endolaser. Time to vitrectomy was 14.8 days ± 8.26 days compared to 629.6 days ± 894.9 days in the immediate and delayed groups, respectively. AUC was significantly greater for patients undergoing delayed versus immediate vitrectomy (276.1 ± 0.601 logMAR*time versus 165.7 ± 0.761 logMAR*time; P < .0001). There was no difference in AUC postoperatively for delayed versus immediate surgery. Both groups required significantly less postoperative panretinal photocoagulation (P < .05). Preoperative and final visual acuities were equivalent (immediate: 1.86 ± 0.99 and 0.35 ± 0.25; P = .002; delayed: 1.71 ± 1.05 and 0.31 ± 0.34; P < .0001).
Immediate vitrectomy with endolaser for PDR-associated VH (< 30 days) decreases time spent with vision loss and the need for adjunctive PRP. Modern vitrectomy is safe and may be considered earlier in VH management.
[Ophthalmic Surg Imaging Lasers Retina. 2016;47:35–41.]
- 1.No authors listed. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol. 1990; 108(7):958–964.
10.1001/archopht.1990.01070090060040Crossref Medline, Google Scholar
- 2.Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014. Google Scholar
- 3.American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4):1033–1046.
10.2337/dc12-2625Crossref Medline, Google Scholar
- 4.Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001; 12(3):230–234.
10.1097/00055735-200106000-00016Crossref Medline, Google Scholar
- 5.Gupta V, Arevalo JF. Surgical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013; 20(4):283–292.
10.4103/0974-9233.120003Crossref Medline, Google Scholar
- 6.Ratnarajan G, Mellington F, Saldanha M, de Silva SR, Benjamin L. Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage. Eye (Lond). 2011; 25(6):704–708; quiz 709.
10.1038/eye.2011.65Crossref Medline, Google Scholar
- 7.Ostri C. Intraocular surgery in a large diabetes patient population: risk factors and surgical results. Acta Ophthalmol. 2014; 92 Thesis1:1–13.
10.1111/aos.12364Crossref, Google Scholar
- 8.Newman DK. Surgical management of the late complications of proliferative diabetic retinopathy. Eye (Lond). 2010; 24(3):441–449.
10.1038/eye.2009.325Crossref Medline, Google Scholar
- 9.Spraul CW, Grossniklaus HE. Vitreous hemorrhage. Surv Ophthalmol. 1997; 42(1):3–39.
10.1016/S0039-6257(97)84041-6Crossref Medline, Google Scholar
- 10.Parikh R, Shah RJ, VanHouten JP, Cherney EF. Ocular findings at initial pan retinal photocoagulation for proliferative diabetic retinopathy predict the need for future pars plana vitrectomy. Retina. 2014; 34(10):1997–2002.
10.1097/IAE.0000000000000192Crossref Medline, Google Scholar
- 11.American Society for Retina Surgeons. Preferences and Trends Survey. 2015. Google Scholar
- 12.Schoenberger SD, Miller DM, Riemann CD, Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging. 2011; 42(6):474–480.
10.3928/15428877-20110901-02Link, Google Scholar
- 13.Gupta B, Sivaprasad S, Wong R, Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study. Eye (Lond). 2012; 26(4):510–516.
10.1038/eye.2011.321Crossref Medline, Google Scholar
- 14.Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol. 1994; 87(3):223–232.
10.1007/BF01203852Crossref Medline, Google Scholar
- 15.No authors listed. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol. 1985; 103(11):1644–1652.
10.1001/archopht.1985.01050110038020Crossref Medline, Google Scholar
- 16.Henderson JM, Ferreira F. The Interface of Language, Vision, and Action: Eye Movements and the Visual World. New York: Psychology Press; 2004:xiv,399. Google Scholar
- 17.Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8):902–916.
10.1001/jama.298.8.902Crossref Medline, Google Scholar
- 18.No authors listed. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology. 1988; 95(10):1307–1320.
10.1016/S0161-6420(88)33015-0Crossref Medline, Google Scholar
- 19.Yeoh J, William C, Allen P, Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008; 36(5):449–454. Medline, Google Scholar
- 20.Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008; 246(6):837–842.
10.1007/s00417-008-0774-yCrossref Medline, Google Scholar
- 21.Ushida H, Kachi S, Asami T, Ishikawa K, Kondo M, Terasaki H. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy. Ophthalmic Res. 2013; 49(1):30–36.
10.1159/000324135Crossref Medline, Google Scholar
- 22.Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond). 2009; 23(1):108–111.
10.1038/sj.eye.6702983Crossref Medline, Google Scholar
- 23.Arevalo JF, Maia M, Flynn H, Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008; 92(2):213–216.
10.1136/bjo.2007.127142Crossref Medline, Google Scholar
- 24.No authors listed. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995; 102(4):647–661.
10.1016/S0161-6420(95)30973-6Crossref Medline, Google Scholar
- 25.No authors listed. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995; 113(1):36–51.
10.1001/archopht.1995.01100010038019Crossref Medline, Google Scholar
- 26.Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD. Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmgenomics Pers Med. 2014; 7:399–409. Medline, Google Scholar